Vertex Pharmaceuticals Inc (VRTX)
473.30
+2.18
(+0.46%)
USD |
NASDAQ |
Nov 04, 16:00
481.00
+7.70
(+1.63%)
After-Hours: 20:00
Vertex Pharmaceuticals Net Income (Annual): 3.620B for Dec. 31, 2023
Net Income (Annual) Chart
Historical Net Income (Annual) Data
Date | Value |
---|---|
December 31, 2023 | 3.620B |
December 31, 2022 | 3.322B |
December 31, 2021 | 2.342B |
December 31, 2020 | 2.712B |
December 31, 2019 | 1.177B |
December 31, 2018 | 2.097B |
December 31, 2017 | 263.48M |
December 31, 2016 | -112.05M |
December 31, 2015 | -556.33M |
December 31, 2014 | -738.56M |
December 31, 2013 | -445.03M |
December 31, 2012 | -107.03M |
December 31, 2011 | 29.57M |
December 31, 2010 | -754.63M |
December 31, 2009 | -642.18M |
December 31, 2008 | -459.85M |
December 31, 2007 | -391.28M |
Date | Value |
---|---|
December 31, 2006 | -206.89M |
December 31, 2005 | -203.42M |
December 31, 2004 | -166.25M |
December 31, 2003 | -196.77M |
December 31, 2002 | -108.62M |
December 31, 2001 | -66.23M |
December 31, 2000 | -34.74M |
December 31, 1999 | -41.00M |
December 31, 1998 | -33.10M |
December 31, 1997 | -19.80M |
December 31, 1996 | -40.00M |
December 31, 1995 | -21.50M |
December 31, 1994 | -17.60M |
December 31, 1993 | 2.00M |
December 31, 1992 | -8.50M |
December 31, 1991 | -5.10M |
December 31, 1990 | -4.30M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Annual) Range, Past 5 Years
1.177B
Minimum
2019
3.620B
Maximum
2023
2.634B
Average
2.712B
Median
2020
Net Income (Annual) Benchmarks
Eli Lilly and Co | 5.240B |
Bristol-Myers Squibb Co | 8.025B |
Regeneron Pharmaceuticals Inc | 3.954B |
Sarepta Therapeutics Inc | -535.98M |
Moderna Inc | -4.714B |